Nabi Biopharma’s latest biotech-stock casualty

Analysts don’t expect shares of the company, which has had much riding on a smoking-cessation product in development, to rebound any time soon.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.